Express Pharma

TAKE Solutions acquires Ecron Acunova

3

Targets the largely untapped biosimilars, regenerative medicine and diagnostic imaging agents space by increasing its IP assets

TAKE Solutions has entered into definitive agreements to acquire a Life Sciences Services player, Ecron Acunova (EA). This association will enable TAKE add expertise in the areas of biosimilars, regenerative medicine and diagnostic imaging agents space which are emerging growth areas. This will help TAKE move the addressable market for its services to $30 billion. It will also significantly enhance its presence in Europe and Nordic countries.

With the coming together of the two organisations, TAKE will explore new vistas of the dynamic pharmaceutical, biotechnology, and medical device R&D markets including the areas of biosimilars, regenerative medicine and diagnostic imaging agents. TAKE’s enhanced capabilities will enable it to be an integral part of the fast growing biosimilars space. As an innovation driven organisation, TAKE will also now be able to expand its IPs in risk-based monitoring and other solutions aimed at bringing safe, effective, and affordable drugs and devices to market.

The organisation will augment its pool of subject matter experts by 30 per cent and life sciences talent by 50 per cent, significantly amplifying its experience, innovation and domain expertise. In addition, the full service capability along with expanded infrastructure will allow TAKE to service the mid-market as well.

Comments are closed.